Vi på TIRmed samarbetar tillsammans med Atopikerna för en patientundersökning. TIRmed Pharma håller just nu på att utveckla en ny kräm...

TIRmed Pharma's project to developing TIR-C has been listed by Kungliga IngenjörsVetenskapsakademien (IVA) in their annual 100 list as...

Vinnova, together with Swelife and Medtech4health, have jointly called for new innovative projects within life science and medical...

TIRmed Pharma have begun a permeability study on their cream targeting Atopic Dermatitis, TIR-C. The study will showcase its ability to...

Eczema is a common disease affecting up to 20% of children and approximately 3% of adults, with a drugs market estimated up to 75 BSEK...

Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide Authors: Aleksandra...

June 17 - 2020

TIRmed Pharma´s proprietary compound to treat inflammatory skin disorders was issued patent approval in the US, April 21st, 2020.